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Rationale: Flow volume loops (FVL) in some bilateral lung transplant
(BLT) and heart–lung transplant (HLT) patients suggest variable ex-
trathoracic obstruction in the absence of identifiable causes. These
FVLs usually have supranormal expiratory and normal inspiratory flow
rates (SUPRA pattern).
Objectives: Characterize the relationship of the SUPRA pattern to
predicted donor and recipient lung volumes, airway size, and survival.
Methods: We performed a retrospective review of adult BLT/HLT
patients. We defined the SUPRA FVL pattern as: (1) mid-vital capacity
expiratory to inspiratory flow ratio (Ve50:Vi50) . 1.0, (2) absence
of identifiable causes of extrathoracic obstruction, and (3) Ve50/
FVC>1.5s21.Wecalculatedpredictedtotal lungcapacity (pTLC) ratio
by dividing the donor pTLC by the recipient pTLC. We measured
airway luminal areas on thoracic computer tomographic scans. We
compared survival in patients with and without the SUPRA pattern.
Measurements and Main Results: The SUPRA FVL pattern occurred in
56% of the 89 patients who qualified for the analysis. The pTLC ratio
of SUPRA and non-SUPRA patients was 1.11 and 0.99, respectively
(P 5 0.004). A higher pTLC ratio was correlated with increased
probability of the SUPRA pattern (P 5 0.0072). Airway luminal areas
were larger in SUPRA patients (P5 0.009). Survival was better in the
SUPRA cohort (P5 0.009).
Conclusions: The SUPRA FVLpattern was frequent in BLT/HLT patients.
High expiratory flows in SUPRA patients could result from increased
lungelastic recoil or reduced airway resistance, both ofwhich could be
caused by the pTLC mismatch. Improved survival in the SUPRA cohort
suggests potential therapeutic approaches to improve outcomes in
BLT/HLT patients.
Keywords: lung transplantation; flow volume loops; lung size mismatch;
dysanapsis; surface tension
Pulmonary function tests (PFT) with flow volume loops (FVL)
are important for the detection of allograft rejection and other
pulmonary complications after lung transplantation. The FVL
ratio of the expiratory flow at mid-vital capacity (Ve50) to the
inspiratory flow at mid-vital capacity (Vi50) is useful to detect
obstructive lesions of the laryngotracheal airway (1, 2). Ve50 is
usually on an effort-independent part of the expiratory flow
volume curve, and Vi50 occurs in the middle of the inspiratory
effort, where it is not affected by rapid acceleration or de-
celeration of flow. Thus Ve50:Vi50 captures the different effects
of intra- or extrathoracic obstruction on inspiratory and expi-
ratory flows. Extrathoracic airway obstruction causes decreased
inspiratory airflow. Therefore, Ve50:Vi50 . 1.0 suggests vari-
able extrathoracic obstruction (1–3). We noted that Ve50:Vi50
frequently exceeded 1.0 in our bilateral lung transplant (BLT)
and heart lung (HLT) transplant patients. However, this pattern
was usually caused by high Ve50, not low Vi50 (Figure 1). We
therefore defined this FVL pattern without anatomic evidence
for extrathoracic obstruction as the supranormal expiratory flow
and pseudo-variable extrathoracic obstruction pattern (SUPRA
FVL). Supranormal expiratory flow after BLT/HLT has been
described previously (4, 5), but we are not aware of reports of
pseudo-variable extrathoracic obstruction. We speculated that
the SUPRA FVL pattern could occur if smaller donor lungs
were transplanted into a larger recipient thorax. This could in-
crease lung tissue elastic recoil at any lung volume and there-
fore increase expiratory airflow (6). However we found that
a major predictor of the SUPRA FVL pattern was the opposite:
larger donor lungs relative to the predicted volume of the re-
cipient thorax. We define the SUPRA FVL pattern and de-
scribe its frequency, airway anatomy, physiology, and clinical
implications in a cohort of BLT/HLT patients. Some of the
results of these studies have been previously reported in the
form of an abstract (7).
METHODS
We analyzed all adult BLTs and HLTs performed at Johns Hopkins
Hospital (JHH) between January 1, 2000 and December 31, 2008.
Single-lung transplant recipients were not assessed due to the potential
impact of the native lung on overall lung function. All adult BLT and
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Scientific Knowledge on the Subject
Flow volume loops (FVL) in some bilateral lung and
heart–lung transplant patients show supranormal expira-
tory flow and suggest variable extrathoracic obstruction in
the absence of identifiable causes.
What This Study Adds to the Field
We defined the supranormal expiratory flow FVL pattern
(SUPRA FVL). The SUPRA pattern occurred in more
than 50% of patients, especially early after transplant.
Restriction of donor lungs in a relatively smaller recipient
thorax is associated with this FVL pattern. The SUPRA
pattern could be caused by increased lung elastic recoil or
decreased airway resistance from relatively larger trans-
planted airways. The association with improved survival
deserves further investigation, which could lead to new
therapeutic strategies to improve clinical outcomes in lung
transplant patients.
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HLT recipients alive 3 months after transplantation with at least two
post-transplant FVLs were included in this study, which was approved
by the Institutional Review Board. All included patients had spirom-
etry, FVLs, and fiberoptic bronchoscopy (FOB) according to the
institutional lung transplant protocol (see online supplement). We
defined the SUPRA FVL pattern as: (1) Ve50:Vi50 . 1.0, (2) supra-
normal expiratory flow with a Ve50/FVC > 1.5 s21, (3) reproducibility
in at least two FVLs obtained on separate days, and (4) absence of
known causes of variable extrathoracic obstruction after review of
FOB reports, medical records, and the lung transplant database.
Bronchiolitis obliterans syndrome (BOS) and acute rejection were
diagnosed according to the standard International Society of Heart and
Lung Transplant criteria (8). An otherwise unexplained greater than
20% decrease from best post-transplant FEV1 was used to diagnose the
onset of BOS. Airway complications were defined as anastomotic or
lower airway stenosis or bronchomalacia that required dilatation, stent
implantation, laser therapy, or endoscopic follow-up.
Analysis of FVLs
The FVLs were analyzed according to time intervals at 1 to 6, 6 to 12,
12 to 24, 24 to 36, and more than 36 months. For any given interval, if
there were multiple FVLs available, the one showing a SUPRA pattern
and/or the one with the highest FVC was included. For each patient
also the FVL with the highest FEV1/FVC ratio was selected (Best-
FVL). Time constant estimate Tau* (21/ln[1 2 FEV1/FVC]), Tau**
(FVC/[2 3 Ve50]), and a slope estimate (Ve50/[0.5 3 FVC]) were
calculated for FVLs of the 1 to 6 month time interval and for Best-
FVLs (9).
Calculation of the Predicted Total Lung Capacity Ratio
The predicted total lung capacity ratio (pTLC) of all donors and
recipients was calculated using regression equations based on height
and sex (10). For each individual patient, size matching between donor
lungs and recipient thorax was expressed as a ratio of donor pTLC to
recipient pTLC (pTLC ratio).
Thoracic Computer Tomographic Airway Analysis
CT scans had been obtained for clinical reasons in some patients. Se-
lection was based on timing (3–6 mo post-transplant, performed 2007
or later) and absence of airway complications or significant pleural
pathology. Airway dimensions were derived from airway luminal area
measurements as previously described and validated (11, 12). Details
about the individual CT scans are summarized in Table E1 and part 3
in the online supplement.
Validation Cohort
All adult BLT/HLT patients transplanted at Inova Fairfax Hospital,
Fairfax, Virginia, with at least two FVLs after transplantation, were
included in the validation cohort to assess the frequency of the SUPRA
FVL pattern and its relation to clinical outcomes. Institutional Review
Board approval was obtained.
Statistical Analysis
Numeric results are expressed as mean 6 SD. Comparisons between
two groups were made with a two-tailed t test, assuming equal var-
iances; one-way analysis or variance; or Fisher exact test as appropri-
ate. Least squares regression models were constructed with the JMP
software program to relate pTLC mismatch and pulmonary function
(www.jmpdiscovery.com). Survival and freedom from BOS were as-
sessed by the Kaplan-Meier method. We evaluated the impact of the
SUPRA pattern on long-term survival using univariable and multivari-
able Cox proportional hazards models. A P value less than 0.05 was
considered significant.
RESULTS
Characteristics of the Johns Hopkins Study Population
There were 107 adult patients who qualified for the analysis, of
whom 99 received a BLT and 8 an HLT (Table 1). Eighty-nine
Figure 1. Flow volume loops of a 65-year-old female patient 2 years
after bilateral lung transplantation for cystic fibrosis, exemplifying the
supranormal expiratory flow and pseudo-variable extrathoracic ob-
struction pattern (SUPRA FVL pattern). The criteria of the SUPRA pattern
are fulfilled by: (1) ratio of the maximal expiratory mid-vital capacity
flow to the maximal inspiratory mid-vital capacity flow (Ve50:Vi50) of
greater than 1.0 (the ratio is 1.5), (2) absence of identifiable causes of
extrathoracic obstruction, (3) supranormal expiratory flow with a Ve50/
FVC ratio of at least 1.5 s21 (the Ve50/FVC is 3.21 s21), and (4)
reproducibility in at least two FVLs. Dashed line indicates expected
expiratory flow rates. BTPS 5 Body Temperature Pressure Saturated.
TABLE 1. CHARACTERISTICS OF 107 ADULT BILATERAL LUNG
AND HEART–LUNG TRANSPLANT PATIENTS TRANSPLANTED AT
THE JOHNS HOPKINS HOSPITAL BETWEEN JANUARY 1, 2000
AND DECEMBER 31, 2008
Characteristics All Included Excluded P Value*
Demographics
No. 107 89 18 —
Sex 48 M, 59 F 38 M, 51 F 10 M, 8 F 0.65
Age, yr (SD) 44.8 (14.0) 44.5 (14.1) 46.5 (13.8) 1.0
Transplant indication
Cystic fibrosis 27 23 4 1.0
COPD 23 23 — 0.011
Pulmonary hypertension 12 9 3 0.42
Sarcoidosis 6 5 1 1.0
Interstitial lung disease 21 15 6 0.12
Congenital heart
disease (HLT)
8 5 3 0.13
Other 10 9 1 1.0
Post transplant
No. of PFTs (SD) 21 (17) 25 (15) 0 (1) 0.023
No. of FOBs (SD) 8 (6) 9 (5) 3 (9) 0.44
Definition of abbreviations: COPD5 chronic obstructive pulmonary disease; F5
female; FOB5 fiberoptic bronchoscopy; HLT5 heart–lung transplant; M5male;
PFT 5 pulmonary function test.
* Comparison of included and excluded patients.
80 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 183 2011
(83%) were alive at 3 months and had at least two FVLs avail-
able for review. The most common reason for exclusion was
death before 3 months after transplantation (14 patients).
Follow-up was complete until time of death or June 28, 2009,
with a mean follow-up period of 3.0 years (range 0.4–9.3 yr).
The data set included 2,206 FVL observations.
Frequency, Time Course and Demographics of the SUPRA
FVL Pattern
The SUPRA FVL pattern occurred in 50 of the 89 patients
analyzed (56%) (Table 2). The mean number of FVLs in the
SUPRA cohort was 27 6 15 and 22 6 14 in the NON-SUPRA
cohort. On average 6 6 4 FVLs in the SUPRA cohort
demonstrated the SUPRA pattern. The SUPRA pattern oc-
curred early in the post-transplant period. At 1 to 6 months
after BLT/HLT, 86 of 89 patients had FVL for review and 47
(55%) displayed this FVL pattern. At subsequent time points
the SUPRA pattern was less frequent (32% for 6–12 mo, 16%
for 12–24 mo, 12% for 24–36 mo, and 14% for . 36 mo; Figure
2). The mean ages, body mass index, number of FVLs, and
FOBs of the patients in the SUPRA and NON-SUPRA cohorts
were similar (Table 2). All the HLT patients included in the
analysis displayed the SUPRA pattern (n 5 5). Among the
different primary diseases, fewer patients with interstitial lung
disease displayed the SUPRA pattern (6% vs. 31%, P 5 0.012),
but there was no difference in the distribution of patterns
among the other primary diseases (Table 2).
Lung Function Characteristics
Spirograms showed lower FVCs in the SUPRA compared with
the NON-SUPRA cohort until 24 months after transplant (P ,
0.05) (Figure E3, Table E2). SUPRA patients showed a moder-
ate reduction in FVC at 1 to 6 months (63.2 6 17% of
predicted). FVC increased over time to 77.46 24% of predicted
at 12 to 24 months and remained mildly reduced at greater than
36 months (81.2 6 21% of predicted). Patients in the NON-
SUPRA cohort tended to have higher FVCs than SUPRA
patients until 24 months (69.86 21% at 1–6 mo and 83.86 18%
at 12–24 mo, comparisons to SUPRA P 5 0.15 and P 5 0.14,
respectively), but FVCs were comparable after 24 months (P 5
0.94). There was a significant difference in the FEV1/FVC ratio
between the cohorts at 1 to 6 months (SUPRA, 0.964 6 0.05 vs.
NON-SUPRA, 0.758 6 0.06, P , 0.001; Table 2). Maximal
expiratory airflows at all lung volumes were higher in the
SUPRA cohort (P , 0.001; Table 2, Figure 3A]). In both
cohorts expiratory flows decreased over time. However, these
TABLE 2. CHARACTERISTICS OF PATIENTS IN THE JOHNS HOPKINS HOSPITAL COHORTS
Characteristic SUPRA NON-SUPRA P Value
Demographics
No. (%) 50 (56) 39 (44) —
Sex 19 M, 31F 19M, 20 F 0.39
Age, yr (SD) 44.2 (14.8) 44.1 (14.1) 1.0
Height, m (SD) 1.64 (0.08) 1.72 (0.1) 0.0014
Weight, kg (SD) 59.3 (13) 62.8 (12) 0.33
Body mass index (SD) 21.8 (4.3) 21.5 (3.5) 1.0
Transplant Indication
Cystic fibrosis (%) 14 (28) 9 (23) 0.63
COPD (%) 12 (24) 11 (28) 0.81
Pulmonary hypertension (%) 6 (12) 3 (8) 0.73
Sarcoidosis (%) 4 (8) 1 (3) 0.38
Interstitial lung disease (%) 3 (6) 12 (31) 0.012
Congenital heart disease (HLT) (%) 5 (10) 0 (0) 0.065
Other (%) 6 (12) 3 (8) 0.73
Post transplant
Mean follow-up time, yr (range) 3.2 (0.5–9.1) 2.7 (0.4–9.3) 0.33
No. of PFTs (SD) 27 (15) 22 (14) 0.9
No. of PFTs with SUPRA pattern 6 0 —
No. of FOBs (SD) 9 (4) 10(6) 1.0
Flow volume loops at 1–6 mo
FVC, L (SD) 2.30 (0.8) 2.64 (1.0) 0.028
FVC, % predicted (SD) 63.2 (20) 69.8 (21) 0.15
FEV1, L (SD) 2.18 (0.8) 2.04 (0.9) 0.45
FEV1, % predicted (SD) 70.3 (25) 64.2 (25) 0.27
FEV1/FVC ratio (SD) 0.946 (0.05) 0.758 (0.15) ,0.001
Tau* 0.31 (0.10) 0.75 (0.50) ,0.001
Tau** 0.24 (0.10) 0.73 (0.49) ,0.001
Slope 4.45 (0.14) 1.63 (0.16) ,0.001
Vemax, L/s (SD) 7.0 (2.2) 5.3 (2.7) ,0.001
Ve75, L/s (SD) 6.2 (1.9) 3.6 (1.8) ,0.001
Ve50, L/s (SD) 4.9 (1.3) 2.1 (1.1) ,0.001
Ve25, L/s (SD) 2.4 (1.2) 1.0 (0.7) ,0.001
Vemax/FVC, s21 (SD) 3.2 (0.8) 1.9 (0.7) ,0.001
Ve75/FVC, s21 (SD) 2.9 (0.8) 1.4 (0.6) ,0.001
Ve50/FVC, s21 (SD) 2.2 (0.6) 0.8 (0.3) ,0.001
Ve25/FVC, s21 (SD) 1.1 (0.6) 0.4 (0.3) ,0.001
Vi50, L/s (SD) 3.4 (1.2) 4.1 (1.6) 0.014
Vi50/FVC, s21 (SD) 1.63 (0.56) 1.62 (0.46) 0.89
Ve50:Vi50 (SD) 1.58 (0.58) 0.53 (0.19) ,0.001
Definition of abbreviations: COPD 5 chronic obstructive pulmonary disease; FOB 5 fiberoptic bronchoscopy; HLT 5 heart–lung
transplant; PFT 5 pulmonary function test; SUPRA 5 supranormal expiratory flow and pseudo-variable extrathoracic obstruction
pattern; Ve 5 expiratory flow; Vi 5 inspiratory flow.
Tau* 5 21/ln[1 2 FEV1/FVC], Tau** 5 FVC/[2 3 Ve50] and slope 5 (Ve50/[0.5 3 FVC]) (8).
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remained higher in the SUPRA cohort at all time points (P ,
0.01; Figures 3A and 3B, Table E3). Because the FVCs were
higher in the NON-SUPRA cohort we normalized maximal
expiratory and inspiratory flows by expressing them as a frac-
tion of FVC. At 1 to 6 months normalized expiratory airflows
were 1.6 to 2.9 times and the mean estimated slope was 2.7
times higher in the SUPRA compared with the NON-SUPRA
cohort (P , 0.001; Table 2, Figure 3B). Normalized inspiratory
flows did not differ between the SUPRA and NON-SUPRA
cohorts at any time point (P . 0.1 for all comparisons; Table
E4). As the selection of FVL according to time intervals might
not allow comparison of the best expiratory flows in each
patient, we also analyzed all Best-FVLs. The Best-FVLs in the
SUPRA patients demonstrated significantly higher expiratory
flows in all parameters in comparison with NON-SUPRA
patients (FEV1/FVC ratio: 0.967 6 0.04 vs. 0.862 6 0.07;
Ve50/FVC ratio: 2.5 6 0.8 s21 vs. 1.2 6 0.4 s21; Tau*: 0.27 6
0.1 and 0.51 6 0.4; and Tau**: 0.21 6 0.1 and 0.48 6 0.4, P ,
0.001 for all).
Helium dilution lung volume measurements were available
in 9 of 50 patients (18%) in the SUPRA cohort and 8 of 39
patients (20%) in the NON-SUPRA cohort (Table 3, online
supplement). The SUPRA cohort demonstrated mild to mod-
erate restriction (TLC 66 6 13% of predicted). The mean
SUPRA vital capacity was decreased to 45 6 16% of predicted.
The mean residual volume (RV) was increased to 112 6 44%
of predicted. The RV/TLC ratio was elevated to 54 6 14% (vs.
336 5% predicted) in the SUPRA patients. The NON-SUPRA
cohort also demonstrated mild restriction (TLC 72 6 12% of
predicted), but the RV/TLC ratio was not elevated (376 6% vs.
34% predicted).
Donor and Recipient Characteristics
Complete demographic information was available for 75 re-
cipient and corresponding donor pairs (Tables 4 and 5). Donors
for SUPRA and NON-SUPRA patients did not differ in their
mean height (1.69 6 0.10 m vs. 1.70 6 0.10 m, P 5 0.7) and
mean pTLC (6.036 1.14 L vs. 6.176 1.14 L, P5 0.6). However,
donors tended to be younger in the SUPRA cohort (38.6 6
13.9 yr vs. 45.2 6 14.4 yr, P 5 0.072). SUPRA recipients were
shorter than NON-SUPRA recipients (1.64 6 0.08 m vs. 1.72 6
0.08 m, P 5 0.0014) and had a lower pTLC (5.49 6 1.0 1 L vs.
6.25 6 1.01 L, P 5 0.0019; Figure 4A). On average the donor
lungs in the SUPRA cohort had a pTLC that exceeded the
recipients’ pTLC by 10.58 L (95% confidence interval [CI],
10.29 to 10.88), whereas in the NON-SUPRA patients, pTLC
of donors and recipients were more closely matched (20.09 L;
95% CI, 20.38 to 10.21). The pTLC ratio was 1.11 (95% CI,
1.06–1.17) in the SUPRA and 0.99 (95% CI, 0.94–1.04) in the
Figure 2. Occurrence of the supranormal expiratory flow and pseudo-
variable extrathoracic obstruction (SUPRA) pattern according to time
interval.
Figure 3. Schematic flow vol-
ume loops (FVLs) derived from
the mean data of 89 bilateral
lung transplant/heart–lung
transplant patients according
to FVL pattern cohort (supra-
normal expiratory flow and
pseudo-variable extrathoracic
obstruction [SUPRA], NON-
SUPRA). (A) Flow expressed in
liters per second. (B) Flow
expressed as a fraction of FVC
(in s21). *Indicates a significant
difference between SUPRA
and NON-SUPRA cohort by
one-way analysis of variance
(P , 0.05). Corresponding ta-
ble is Table E3. Sec 5 seconds.
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NON-SUPRA cohort (P 5 0.004; Figure 4B). Logistic re-
gression analysis showed a significant correlation between
a high pTLC ratio and the probability of the SUPRA pattern
(P 5 0.0072; Figure 4C). No other factor besides height
mismatch (P5 0.0024) was associated with the SUPRA pattern.
Airway Dimension Analysis
There were 10 patients in the SUPRA and 5 patients in the
NON-SUPRA cohort who qualified for airway dimension
analysis from thoracic high-resolution computed tomography
scans (HRCTs) (see online supplement). On average, 24 6
4 individual airways were measurable per patient (range 5.6–
496.2 mm2 in area). To compare airway luminal area measure-
ments, we calculated the average of the individual airway
luminal areas within each cohort (Table 6, Table E6). The
SUPRA patients had significantly larger transplanted airways
compared with the NON-SUPRA patients (P 5 0.009). This
was true for lobar and larger (e.g., bronchus intermedius, P 5
0.03) and segmental airways, but the difference for segmental
airways did not reach significance (P 5 0.09). Because some
airway measurements were not available in some patients, we
reanalyzed the comparisons including only airway measure-
ments available in at least 80% of patients in both cohorts. This
allowed comparisons of 12 instead of 26 airways (marked by ** in
Table E6). The airways in the SUPRA cohort remained signif-
icantly larger (P, 0.05). The cohorts differed in height (SUPRA
1.68 6 0.08 m vs. NON-SUPRA 1.73 6 0.07 m, P 5 0.29) and in
native airway size. We adjusted the airway measurements by
dividing each individual airway luminal area by the height of the
patient. We also adjusted the airway sizes by dividing each trans-
planted airway luminal area by the recipient’s native tracheal
luminal area. After both corrections, the difference between
groups became greater (Table 6). After adjustments, the average
airway luminal area was 51 to 54% larger in the SUPRA com-
pared with the NON-SUPRA cohort (P 5 0.0003). Two patients
in the SUPRA cohort were transplanted for pulmonary vascular
causes and had no significant airways disease. In these patients
Figure 4. Size mismatch between larger donor
lungs and smaller recipient thorax as a predictor
of the supranormal expiratory flow and pseudo-
variable extrathoracic obstruction (SUPRA) pat-
tern. (A) Predicted total lung capacity (pTLC) for
recipients and donors in the SUPRA and NON-
SUPRA cohort. *Indicates a significant difference
between SUPRA and NON-SUPRA cohort by
one-way analysis of variance (P , 0.05). (B)
Lung size mismatch expressed as the pTLC ratio
(pTLC Donor/pTLC Recipient) in SUPRA and
NON-SUPRA cohorts (comparison by one-way
analysis of variance). The solid horizontal lines
represent mean and 95% confidence interval of
the mean. The dashed line represents exact
matching of donor and recipient (pTLC ratio
of 1.0). (C) Logistic regression analysis showed
a significant correlation between a high pTLC
ratio and the probability of the SUPRA pattern
(P 5 0.0072).
TABLE 3. SPIROMETRY AND CORRESPONDING HELIUM DILUTION LUNG VOLUME MEASUREMENTS
SUPRA (n 5 9) NON-SUPRA (n 5 8)
Measure Time, mo
13.3 6 13 19.6 6 11
Parameter Actual (SD) Pred. (SD) % Pred. (SD) Actual (SD) Pred. (SD) % Pred. (SD)
Spirometry
FVC 1.8 (0.8) 3.6 (0.8) 49.0 (15.4) 2.9 (0.9) 4.2 (0.8) 68.4 (14.6)
FEV1 1.49 (0.9) 2.9 (2.9) 48.6 (18.9) 1.8 (0.7) 3.4 (0.7) 52.4 (14.8)
FEV1/FVC 81.6 (13.6) 83.0 (2.2) 62.5 (13.2) 81.2 (1.4)
Helium dilution
TLC 3.5 (1.0) 5.2 (0.8) 65.6 (12.9) 4.5 (1.1) 6.3 (1.3) 71.6 (12.1)
VC 1.65 (0.8) 3.3 (0.6) 45.2 (16.3) 2.9 (0.9) 4.2 (0.8) 68.4 (15.2)
FRC 2.4 (0.4) 2.9 (0.4) 81.1 (22.2) 2.6 (0.5) 3.6 (0.8) 71.9 (7.8)
RV 1.85 (0.7) 1.7 (0.1) 112.3 (44.0) 1.6 (0.4) 2.1 (0.4) 77.5 (16.1)
RV/TLC 53.7 (14) 32.5 (5.0) 37.1 (6.8) 34.1 (1.8)
Definition of abbreviations: pred. 5 predicted; RV 5 residual volume; SUPRA 5 supranormal expiratory flow and pseudo-variable extrathoracic obstruction
pattern.
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we compared airway luminal area measurements from CT scans
before and after transplantation. The average luminal area was
32% larger on the post-transplant CT in one (P 5 0.02) and 19%
larger in the other patient (P 5 0.06) (Tables E7 and E8).
Clinical Outcomes
The mean follow-up time was 3.0 years (range 0.4–9.3 yr), and
30 deaths occurred (Table 7). The most common causes of
death were BOS (37%), BOS complicated by infection (26%),
infection (13%), and malignancy (10%). In the SUPRA cohort,
with a mean follow-up of 3.2 years (range 0.5–9.1 yr), 11 deaths
occurred. In the NON-SUPRA cohort, with a mean follow up of
2.7 years (range 0.4–9.3 yr), 19 deaths occurred. The SUPRA
pattern was associated with a significantly better survival (P 5
0.009; Figure 5A). Estimated 5-year survival rates were 70% in
the SUPRA and 28% in the NON-SUPRA cohort. The
SUPRA and NON-SUPRA cohorts did not differ significantly
regarding causes of mortality, occurrence of BOS, or acute
rejection. However, airway complications were more common
in the NON-SUPRA cohort (12 vs. 41%, P 5 0.0026). In uni-
variable Cox proportional hazard regression models the pres-
ence of BOS (P 5 0.003), the presence of the SUPRA pattern
(P 5 0.014), Ve50 (P 5 0.03), and Ve50/FVC (P 5 0.03) were
associated with survival (Table 8). Acute rejection, airway com-
plications, transplant indications, recipient and donor age, and
pTLC ratio were not associated with survival. To examine the
effect of the SUPRA pattern on survival in the context of BOS
we constructed a multivariable Cox proportional hazard re-
gression model. The SUPRA pattern remained associated with
better survival (relative risk, 0.41; 95% CI, 0.21–0.93; P 5 0.033;
Table 8). Although the occurrence of BOS did not differ
significantly between SUPRA and NON-SUPRA cohorts (P 5
0.1), mean time from transplant to BOS diagnosis was longer in
SUPRA patients (1.89 6 0.85 yr vs. 0.97 6 0.71 yr, P 5 0.003).
At all time points SUPRA patients were more likely to be BOS
free (P 5 0.01; Figure 5B). SUPRA patients diagnosed with
BOS had a trend toward better survival compared with NON-
SUPRA patients with BOS (P 5 0.08).
The SUPRA FVL Pattern in the Inova Fairfax Hospital Cohort
There were 43 patients who had at least two FVLs available for
review (see online supplemental information and Table E10).
The SUPRA FVL pattern occurred in 49% of patients. The
mean follow-up was 3.8 years, and 14 deaths occurred. Five
deaths occurred in the SUPRA and 9 deaths in the NON-
SUPRA cohort. There was a trend toward better survival of the
SUPRA cohort (P 5 0.12).
DISCUSSION
In this report we describe the SUPRA FVL pattern in a cohort
of BLT and HLT patients. The SUPRA FVL pattern is com-
mon, occurring in more than 50% of patients, and its presence is
associated with improved survival. Contrary to our initial hy-
pothesis, the pTLC of donor lungs was generally larger than
recipient pTLC, which was associated with lower FVCs and
higher expiratory flow capacities. CT airway dimension analysis
showed significantly larger airway luminal areas in SUPRA
patients compared with NON-SUPRA patients.
Physiology of the SUPRA FVL Pattern
The key feature of the SUPRA FVL pattern is the supranormal
expiratory flow. At 1 to 6 months after transplantation, the
FEV1/FVC ratio was 0.964 6 0.05. The Ve50/FVC ratio in the
SUPRA cohort was 2.8 times greater than in the NON-SUPRA
cohort and 2.2 times greater than would be predicted for the
SUPRA FVC (13). Further key characteristics of the SUPRA
pattern were lower FVCs and a high RV/TLC ratio. Each of
these features could be explained by the observed mismatch
between relatively larger donor lungs transplanted into a re-
cipient with a smaller pTLC. A theoretical model of lung
volume changes caused by lungs that are larger in relation to
the size of the thorax predicted a high RV/TLC ratio (14). A
similar pattern of an elevated RV/TLC ratio was reported in
seven HLT patients who had received significantly larger donor
lungs (mean pTLC ratio 1.30), for whom 1 year after transplant
the RV was in the predicted range for the (larger) donor lungs,
whereas TLC was in the predicted range for the recipient (15).
In younger individuals RV is determined by chest wall mechan-
ics and not airway closure (16). The age of donor lungs and the
terminal slope of FVLs in the SUPRA cohort suggest that RV is
determined by recipient chest wall mechanics or termination of
effort. The elevated RV/TLC ratio and decreased TLC may also
explain the lower FVCs in the SUPRA cohort. Thus, the sup-
ranormal expiratory flow capacity in SUPRA patients could be
a result of the lung size mismatch.
Size Mismatch Could Cause High Expiratory Flow
A mismatch between relatively larger donor lungs transplanted
into a smaller thorax could affect airway resistance because of
dysanapsis. This term was used by Green and colleagues to
TABLE 4. DONOR AND RECIPIENT CHARACTERISTICS IN THE
SUPRANORMAL EXPIRATORY FLOW AND PSEUDO-VARIABLE
EXTRATHORACIC OBSTRUCTION PATTERN COHORT
Characteristic
SUPRA (n 5 41)
Parameter Recipient Donor Mismatch P Value
Age, yr (SD) 44.2 (14.8) 38.6 (13.9) 26.9 (18) ,0.03
Height, m (SD) 1.64 (0.08) 1.69 (0.11) 10.05 (0.09) ,0.002
Weight, kg (SD) 59.3 (13) 77.5 (20.4) 117.9 (24) ,0.001
BMI (SD) 21.8 (4.3) 27.6 (7.5) 15.2 (8) ,0.001
pTLC, L (SD) 5.49 (1.0) 6.03 (1.1) 10.58 (0.81) ,0.0004
pTLC ratio (95% CI) 1.11 (1.06–1.18)*
Definition of abbreviations: BMI 5 body mass index; CI 5 confidence interval;
pTLC 5 predicted total lung capacity; SUPRA 5 supranormal expiratory flow and
pseudo-variable extrathoracic obstruction pattern.
pTLC of each donor and recipient was calculated using the regression
equations recommended by the American Thoracic Society/European Respiratory
Society (9). Comparisons of donors and recipients within each cohort were made
with a Student t test.
* Comparison of pTLC ratio SUPRA vs. NON-SUPRA cohort by one-way analysis
of variance: P 5 0.004.
TABLE 5. DONOR AND RECIPIENT CHARACTERISTICS IN THE
NON–SUPRANORMAL EXPIRATORY FLOW AND PSEUDO-
VARIABLE EXTRATHORACIC OBSTRUCTION PATTERN COHORT
Characteristic
NON-SUPRA (n 5 34)
Parameter Recipient Donor XMismatch P Value
Age, yr (SD) 44.4 (14.1) 45.2 (14.4) 0.3 (17) 0.92
Height, m (SD) 1.72 (0.10) 1.70 (0.10) 20.02 (0.1) 0.13
Weight, kg (SD) 62.8 (12.1) 79.0 (22.5) 115.5 (24) ,0.001
BMI (SD) 21.5 (3.5) 27.7 (7.2) 16.1 (8) ,0.001
pTLC, L (SD) 6.25 (1.01) 6.17 (1.14) 20.09 (0.8) 0.55
pTLC ratio (95% CI) 0.99 (0.94–1.04)*
For definition of abbreviations see Table 4.
pTLC of each donor and recipient was calculated using the regression
equations recommended by the American Thoracic Society/European Respiratory
Society (9). Comparisons of donors and recipients within each cohort were made
with a Student t test.
* Comparison of pTLC ratio SUPRA vs. NON-SUPRA cohort by one-way analysis
of variance: P 5 0.004.
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describe a size mismatch between airways relative to an in-
dividual’s lung and thorax volume (13). Green and colleagues
found a correlation between the interindividual variability in
the expiratory FVL and the structure of the larger airways (13).
Mead quantified dysanapsis by the ratio of a measurement
known to be sensitive to airway size (Ve50) to a measurement
of lung size (FVC) (17). The normal range of the Ve50/FVC
ratio is 1.0 to 1.3 s21 (12). In the SUPRA cohort the Ve50/FVC
ratio at 1 to 6 months post-transplant was 2.23 6 0.6 s21 (vs.
0.826 0.34 s21 in NON-SUPRA cohort). Our analysis of airway
dimensions on HRCT scans showed significantly larger trans-
planted airways in SUPRA compared with NON-SUPRA
patients (P 5 0.009). The difference in airway dimensions
between the cohorts and the corresponding differences in
expiratory flow capacity suggests that the structure of trans-
planted airways is important for post-transplant lung function.
Furthermore an HRCT study of patients with moderate asthma
demonstrated a significant correlation between the diameter of
larger airways, the FEV1/FVC ratio, and airway hyperrespon-
siveness (18). An association between transplanted lungs that
were smaller than the recipient’s thorax and airway hyper-
responsiveness was reported in a cohort of lung transplant
patients (19).
Elastic recoil could also be affected by lung size mismatch.
Decreased elastic recoil might be predicted from transplanting
larger donor lungs into a smaller recipient thorax (13). How-
ever, changes in surface tension could counteract this effect and
lead to an overall increase in elastic recoil (20). Chest wall
strapping, a situation conceptually similar to a size mismatch of
a relatively larger lung in relation to a restricted thorax, causes
increased elastic recoil of the lungs (21–23). In eight normal
males, chest wall strapping caused a reduction of VC and FRC
by about 40%, whereas RV decreased by only 11% (22). Elastic
recoil was increased by 64%. This was associated with an
increase in Ve50 by 88% and an increase in the Ve50/VC ratio
by 302% (22). Increased recoil pressure from limiting full
inspiration and breathing close to RV is best explained by
changes in surface tension (22, 24). This effect seems to persist
over time and is not related to atelectasis (25). Breathing close
to RV and limited inspiration would be expected from trans-
plantation of lungs that are larger than a recipient’s thorax. This
could also cause increased elastic recoil, which is a critical de-
terminant of maximum expiratory flow (6). Chacon and col-
leagues analyzed respiratory mechanics in 15 BLT/HLT
patients with a mean pTLC ratio of 1.09 and found the elastic
recoil of the transplanted lungs to be mildly increased (26).
Increases in elastic recoil and higher expiratory flow rates have
also been described for limitations of inspiration caused by
pleural effusions and pneumothorax (27). The frequency of
pleural pathology in our cohort was high, but there was no
difference in frequency between SUPRA and NON-SUPRA
cohorts (see online supplement).
The SUPRA FVL Pattern and Survival
The SUPRA FVL pattern was associated with significantly
better survival (P , 0.009; Figure 5A). The leading cause of
long-term mortality after lung transplantation is BOS, which is
believed to be due to chronic allograft rejection (8, 28). BOS
has a prevalence of about 70% at 5 years and is characterized by
a progressively worsening obstructive ventilatory defect (28).
Although the overall occurrence of BOS did not differ signif-
icantly between SUPRA and NON-SUPRA cohorts, time to
BOS diagnosis was longer in the SUPRA cohort, and at all
time points SUPRA patients were less likely to have BOS
(Figure 5B). Furthermore, higher expiratory flows in the
SUPRA cohort in the first 6 to 12 months after transplantation
could have provided a reserve that resulted in improved survival
in patients subsequently affected by BOS. Indeed we found
a trend toward better survival in SUPRA patients affected by
BOS in comparison to NON-SUPRA patients with BOS.
TABLE 6. AIRWAY DIMENSIONS BY THORACIC HIGH-RESOLUTION COMPUTED TOMOGRAPHY SCANS
Absolute Area (mm2) Height corr. Area (mm2/m)* % of Tracheal Area† No. of Patients
SUPRA NON- SUPRA SUPRA NON- SUPRA SUPRA NON- SUPRA SUPRA NON- SUPRA
Native airways (trachea) 307 353 183 204 N/A N/A 10 5
P value (native) 0.2 0.37 N/A
Lobar and larger airways 90.6 64.0 53.6 31.0 31.0 17.4 8.9 3.5
P value (lobar and larger)‡ 0.03 0.005 0.003
Segmental airways 32.4 28.6 19.2 14.5 11.1 8.1 7.8 3.5
P value (segmental)x 0.09 0.005 0.006
Combined (lobar/larger and
segmental) airways
48.1 39.2 28.5 18.9 16.4 10.6 8.1 3.5
P value (combined)k 0.009 0.0003 0.0003
Definition of abbreviations: corr. 5 corrected; N/A 5 not applicable; SUPRA 5 supranormal expiratory flow and pseudo-variable extrathoracic obstruction pattern.
Table E6 provides details on individual airway luminal area measurements. Figure E2 shows an airway tree diagram with assigned labels of airway segments.
* Correction for height by dividing each individual airway luminal area by the height of the individual recipient.
† Correction by expressing each transplanted airway luminal area as a fraction of each recipient’s native tracheal luminal area.
‡ Comparison of the all individual lobar and larger airway diameters between SUPRA and NON-SUPRA cohort.
x Comparison of all individual segmental conductive airway diameters between SUPRA and NON-SUPRA cohort.
k Comparison of all individual lobar/larger and segmental conductive airway diameters between SUPRA and NON-SUPRA cohort.
TABLE 7. THE SUPRANORMAL EXPIRATORY FLOW AND
PSEUDO-VARIABLE EXTRATHORACIC OBSTRUCTION FLOW
VOLUME LOOP PATTERN AND CLINICAL OUTCOMES IN THE
JOHNS HOPKINS HOSPITAL COHORT
Clinical Outcome SUPRA NON-SUPRA P Value
No. 50 39
Mean follow-up, yr (range) 3.2 (0.5–9.2) 2.7 (0.4–9.3) 0.33
Airway complications (%) 6 (12) 16 (41) 0.0026
Acute rejection (%) 17 (34) 16 (41) 0.76
Diagnosis of BOS (%) 13 (26) 17 (43) 0.1
Time to BOS diagnosis, yr (SD) 1.89 (0.85) 0.97 (0.70) 0.003
Patients with BOS alive 7 (54) 5 (29) 0.08
Dead at last follow-up (%) 11 (22) 19 (49) 0.0125
Causes of mortality (%)
BOS 3 (27) 8 (42) 0.053
Infection 1 (9) 3 (16) 0.32
BOS 1 infection 4 (36) 4 (21) 0.73
Malignancy 1 (9) 2 (11) 0.58
Other 2 (18) 2 (11) 1.0
Definition of abbreviations: BOS 5 bronchiolitis obliterans syndrome; SUPRA 5
supranormal expiratory flow and pseudo-variable extrathoracic obstruction pattern.
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Decreased surfactant protein levels have been reported after
lung transplantation, and this was associated with onset of BOS
after transplantation (29, 30). In models of decreased lung
compliance, increases in surfactant protein and phospholipid
content occurred (31, 32). Changes in surfactant resulting from
transplantation of a larger lung to a smaller recipient thorax
could have implications for the timing and occurrence of BOS.
Several investigators have reported clinical outcomes after lung
transplantation with donor–recipient size mismatches. No asso-
ciation with clinical outcomes was found, except in the in-
vestigation that included the largest number of patients (33–36).
This study of 520 BLT/single lung transplant patients showed
worse survival with transplanting smaller donor lungs in relation
to the recipient thorax (36). We found no significant association
between the pTLC ratio and survival. Using pTLC to esti-
mate the relationship between donor lungs to recipient (post-
transplant) thorax appears to be imprecise.
It is unclear if increased elastic recoil or larger airways is the
predominant factor causing the supranormal expiratory flow. If
larger airways is the key factor, then a direct airway assessment
of airway anatomy of potential donors could be part of the
donor evaluation process. If increased elastic recoil is the pre-
dominant factor, then surgical strategies to manipulate the
recipient thorax size (i.e., plombage) could be considered. Fur-
thermore, the hypothesis of surfactant changes after transplan-
tation in relation to size mismatch and its association with BOS
should be investigated, as this could inform studies of surfactant
replacement strategies after lung transplantation (37, 38).
Our investigation has several limitations. It is a primarily
a single-center study and retrospective in its design. However
our findings are supported and validated by review of FVLs in
an independent BLT/HLT cohort from another program. We
have no data on elastic recoil to support our hypothesis of
increased elastic recoil in the SUPRA cohort. We demonstrated
a significant relationship between lung size mismatch and the
presence of the SUPRA pattern, but there was substantial
overlap in the ranges of the pTLC ratio between SUPRA and
NON-SUPRA patients. The helium lung volume measurements
showing an elevated RV/TLC ratio and the HRCT analysis
demonstrating larger airways in SUPRA patients are limited by
the small number of patients analyzed in each cohort and the
clinical indication for these studies. The quality of the CT scans
allowed us to only analyze airways up to the segmental bronchi.
It remains unclear how smaller airways or changes in the chest
wall mechanics over time might contribute to the physiology of
the SUPRA FVL pattern.
Conclusions
We defined the SUPRA FVL pattern and found that it is
common, especially in the early post-transplant period. The key
feature of the SUPRA FVL pattern is the supranormal expira-
tory flow. Restriction of donor lungs in a relatively smaller
recipient thorax could cause the SUPRA FVL pattern. In-
creased elastic recoil from limitations on inspiration and lower
airway resistance from larger transplanted airways may explain
the supranormal expiratory flow. The association with improved
survival deserves further investigation, which could lead to new
therapeutic strategies to improve clinical outcomes in lung
transplant patients.
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TABLE 8. COX PROPORTIONAL HAZARDS MODELS OF RISK
FACTORS FOR DEATH
Risk Factor RR 95% CI P Value
Univariable
Recipient age (per yr) 0.98 0.95–1.01 0.26
Donor age (per yr) 1.03 0.99–1.07 0.15
pTLC ratio 0.33 0.04–2.52 0.28
pTLC ratio . 1.0 0.73 0.35–1.56 0.42
Transplant indications
Cystic fibrosis 1.47 0.67–3.22 0.33
COPD 1.07 0.46–2.50 0.88
Congenital heart disease — — 0.96
Interstitial lung disease 1.43 0.54–3.79 0.47
Pulmonary hypertension 0.88 0.30–2.53 0.81
Sarcoidosis 0.63 0.15–2.69 0.54
Other 0.71 0.22–2.34 0.57
Occurrence of acute rejection 1.27 0.63–2.63 0.49
Occurrence of airway complication 1.52 0.71–3.24 0.28
Occurrence of BOS 3.06 1.47–6.37 0.003
Presence of SUPRA pattern 0.38 0.18–0.81 0.01
Flow volume loops (1–(6 mo)
Ve50 0.78 0.62–0.97 0.03
Ve50/FVC 0.59 0.36–0.95 0.03
Ve50:Vi50 0.73 0.40–1.33 0.30
Multivariable
Occurrence of BOS 2.75 1.30–5.81 0.008
Presence of SUPRA pattern 0.44 0.21–0.93 0.03
Definition of abbreviations: BOS 5 bronchiolitis obliterans syndrome; COPD 5
chronic obstructive pulmonary disease; pTLC 5 predicted total lung capacity;
SUPRA 5 supranormal expiratory flow and pseudo-variable extrathoracic ob-
struction pattern; Ve 5 expiratory flow; Vi 5 inspiratory flow.
Model chi-square 5 13.6, P , 0.001.
Figure 5. The supranormal
expiratory flow and pseudo-
variable extrathoracic obstruction
(SUPRA) pattern is associated
with clinical outcomes. (A)
Kaplan-Meier survival esti-
mates for patients in SUPRA
and NON-SUPRA flow-volume
loop patients in the Johns Hop-
kins Hospital cohort. (B)
Kaplan-Meier estimates for
the probability of being free
of bronchiolitis obliterans syn-
drome (BOS).
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